Filing Flows › Health Care › Cytosorbents (CTSO)
Cytosorbents (CTSO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 6, 2026 · Cytosorbents (CTSO) Q2 2026 earnings results →
Q2 2026 Revenue up 0% year over year to $9.6M · 46¢ of every $1 of revenue lost · operating margin -27.4%
Cytosorbents made $9.6M in Q2 2026 (+0.2% Y/Y). Operating margin -27.4%, net loss $4.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $9.6M in Q2 2026, roughly flat year over year and up 9% from the previous quarter.
Gross margin was 73.2%, up 2.3 points from Q2 2025. Operating costs exceeded revenue by $2.6M, an operating margin of -27.4%. Operating expenses fell 7% while revenue was flat. The fastest-growing cost line was Research & development (+15%). The quarter ended with a net loss of $4.4M, narrower than the previous quarter's $5.1M loss.
Operating cash flow was −$583K. Non-cash charges added back $360K of depreciation and amortization and $368K of share-based compensation. Working capital and other items added $3.1M. Capital expenditures of $14K exceeded it, leaving free cash flow of −$597K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 6, 2026 | $9.6M | +0.2% | -27.4% | −$4.4M | −$583K |
| Q1 2026 | 10-Q | May 13, 2026 | $8.9M | +2% | -34.3% | −$5.1M | −$1.2M |
| Q4 2025 | 10-K | Mar 30, 2026 | $9.2M | +0.9% | -47.5% | −$5.5M | −$4.8M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $9.5M | +10% | -30.2% | −$3.2M | −$2.6M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $9.6M | +9% | -37.6% | $1.9M | −$1.5M |
| Q1 2025 | 10-Q | May 14, 2025 | $8.7M | -3% | -44.6% | −$1.5M | −$3.5M |
| Q4 2024 | 10-K | Mar 31, 2025 | $6.5M | -25% | -52.0% | −$7.6M | −$2.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cytosorbents
We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents’ technologies are used in a number of broad applications.
In its own words, from its 10-K, filed Mar 30, 2026.
Cytosorbents against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +0.2% against the peers' median +5%. Operating margin: -27.4% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CTSO Cytosorbents | Q2 2026 | $9.6M | +0.2% | -27.4% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Cytosorbents 10-Q on SEC EDGAR · CIK 1175151 · Surgical & Medical Instruments & Apparatus
More on CTSO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results